Tissue factor-driven thrombin generation and inflammation in atherosclerosis

Thrombosis Research

Volumn 129, Issue SUPPL. 2, 2012, Pages

  Ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DABIGATRAN; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 84859797779     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.028     Document Type: Article

References (35)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26. (Pubitemid 29054847)
2. Borissoff J, SpronkHMH, ten Cate H. The hemostatic systemas amodulator of atherosclerosis. N Engl J Med 2011;364:1746-60.
3. Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998;101(9):1983-91. (Pubitemid 28226118)
4. Bea F, Kreuzer J, PreuschM, Schaab S, Isermann B, Rosenfeld ME, et al. Melagatran reduces advanced atherosclerotic lesion size andmay promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006;26(12):2787-92.
5. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apoE-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011 2011:432080. Epub 2011 Jun 7.
6. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989;86:2839-43. (Pubitemid 19112635)
7. Pawlinski R, Pedersen B, Erlich J, Mackman N. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004;92:444-50. (Pubitemid 39248000)
8. Osterud B. Tissue factor expression in blood cells. Thromb Res 2010;125:S31-4.
9. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113(5):722-31.
10. Carmeliet P,MackmanN,Moons L, Luther T, Gressens P, Van Vlaenderen I, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383(6595):73-5.
11. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze Jr GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88(5):1583-7. (Pubitemid 26307052)
12. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmbäck K, Danton MJ, et al. Fatal embryonic bleeding events inmice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996;93(13):6258-63.
13. Chen J, Bierhaus A, Schiekofer S, AndrassyM, Chen B, Stern DM, et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86(1):334-45. (Pubitemid 32663964)
14. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007;5(6):1097-105. (Pubitemid 46902106)
15. Van den Hengel LG, Versteeg HH. Tissue factor signaling: a multi-faceted function in biological processes. Front Biosci 2011;S3L:1500-10.
16. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflamm 2011;2011:367284.
17. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000;28(9 Suppl.):S9-S11.
18. Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease. Circ J 2010;74:3-12.
19. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping P. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999;94(10):3413-20. (Pubitemid 29536136)
20. Demetz G, Suitz I, Stein A, Steppich B, Groha P, Brandl R, et al. Tissue factor-factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis 2010;212:466-71.
21. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernández-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95(3):594-9. (Pubitemid 27063034)
22. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissuefactor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349(9054):769-71.
23. Borissoff J, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010 Aug 24;122(8):821-30 Epub 2010 Aug 9.
24. Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, Shen Y, et al. Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 2006;26:555-62.
25. Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR. Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice. Atherosclerosis 2009;205(2):427-32 Epub 2009 Jan 23.
26. Spronk HM, van der Voort D, Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2004;2(1):12.
27. Makin AJ, Chung NAY, Silverman SH, Lip GYH. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci 2003;104:397-404. (Pubitemid 36458066)
28. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996;2(1):35-40. (Pubitemid 26028070)
29. Holroyd E, Simari RD. Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation. Thromb Res 2010;125:S57-9 (Suppl.).
30. Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, van der Voort D, et al. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. J Thromb Haemost 2009;7:290-8.
31. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatinmediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003;167(2):187-94. (Pubitemid 36773519)
32. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002;22(9):1452-8.
33. Regnault V, Perret-Guillaume C, Kearney-Schwartz A, Max JP, Labat C, Louis H, et al. Tissue factor pathway inhibitor: a new link among arterial stiffness, pulse pressure, and coagulation in postmenopausal women. Arterioscler Thromb VascBiol 2011;31(5):1226-32.
34. Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans G, Castoldi E, et al. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011;9(11):2243-50.
35. Shirk RA, Vlasuk GP. Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007;27:1895-900. (Pubitemid 47312296)